Detalhe da pesquisa
1.
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer.
Ann Oncol
; 28(10): 2436-2442, 2017 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28961836
2.
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).
Ann Oncol
; 26(5): 865-872, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25070543
3.
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).
Ann Oncol
; 26(5): 873-879, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25725046
4.
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).
Ann Oncol
; 26(12): 2505-6, 2015 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-26467471
5.
[Editorial]. / Éditorial.
Rev Epidemiol Sante Publique
; 63 Suppl 2: S35-6, 2015 May.
Artigo
Francês
| MEDLINE | ID: mdl-25882855
6.
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).
Ann Oncol
; 20(4): 674-80, 2009 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-19179549
7.
Two-part statistics with paired data.
Stat Med
; 24(9): 1435-48, 2005 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-15565738